Literature DB >> 22811841

Pancreatic cancer: current standards, research updates and future directions.

Chung-Tsen Hsueh1.   

Abstract

Entities:  

Year:  2011        PMID： 22811841      PMCID： PMC3397612          DOI： 10.3978/j.issn.2078-6891.2011.037

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  23 in total

1.  Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience.

Authors:  C Max Schmidt; Olivier Turrini; Purvi Parikh; Michael G House; Nicholas J Zyromski; Atilla Nakeeb; Thomas J Howard; Henry A Pitt; Keith D Lillemoe
Journal:  Arch Surg       Date:  2010-07

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Long-term patterns of morphine dosage and pain intensity among cancer patients.

Authors:  P Sloan; R Melzack
Journal:  Hosp J       Date:  1999

4.  Adjuvant therapy in pancreatic cancer.

Authors:  Amy Thomas; Khaled Dajani; John P Neoptolemos; Paula Ghaneh
Journal:  Dig Dis       Date:  2010-11-18       Impact factor: 2.404

5.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Authors:  John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler
Journal:  JAMA       Date:  2010-09-08       Impact factor: 56.272

6.  Variations in referral patterns to high-volume centers for pancreatic cancer.

Authors:  David C Chang; Yiyi Zhang; Debraj Mukherjee; Christopher L Wolfgang; Richard D Schulick; John L Cameron; Nita Ahuja
Journal:  J Am Coll Surg       Date:  2009-12       Impact factor: 6.113

7.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

8.  Outcomes following pancreatic resection: variability among high-volume providers.

Authors:  Taylor S Riall; William H Nealon; James S Goodwin; Courtney M Townsend; Jean L Freeman
Journal:  Surgery       Date:  2008-08       Impact factor: 3.982

9.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

10.  Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology.

Authors:  Milind Javle; Chung-Tsen Hsueh
Journal:  J Hematol Oncol       Date:  2009-02-23       Impact factor: 17.388
View more
  8 in total

1.  JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells.

Authors:  Zhe Liu; Ruixia Du; Jin Long; Anbing Dong; Jianpeng Fan; Kejian Guo; Yuanhong Xu
Journal:  Tumour Biol       Date:  2012-04-27

2.  Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer.

Authors:  Gary Y Yang; Nadia K Malik; Rameela Chandrasekhar; Wen-Wee Ma; Leayn Flaherty; Renuka Iyer; Boris Kuvshinoff; John Gibbs; Gregory Wilding; Graham Warren; Kilian Salerno May
Journal:  J Gastrointest Oncol       Date:  2013-12

3.  Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration.

Authors:  Chiara Birtolo; Hung Pham; Susan Morvaridi; Chintan Chheda; Vay Liang W Go; Andrzej Ptasznik; Mouad Edderkaoui; Michael H Weisman; Erika Noss; Michael B Brenner; Brent Larson; Maha Guindi; Qiang Wang; Stephen J Pandol
Journal:  Am J Pathol       Date:  2016-11-14       Impact factor: 5.770

4.  DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.

Authors:  Qingqu Guo; Wenjie Qin
Journal:  J Cell Mol Med       Date:  2015-09-23       Impact factor: 5.310

5.  The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma.

Authors:  Yu-Jiang Li; Gui-Lin Huang; Xu-Ling Sun; Xin-Chun Zhao; Zhi-Gang Li
Journal:  World J Surg Oncol       Date:  2016-02-29       Impact factor: 2.754

Review 6.  High-intensity focused ultrasound treatment for advanced pancreatic cancer.

Authors:  Yufeng Zhou
Journal:  Gastroenterol Res Pract       Date:  2014-06-26       Impact factor: 2.260

7.  Response of patients with locally advanced pancreatic adenocarcinoma to high-intensity focused ultrasound treatment: a single-center, prospective, case series in China.

Authors:  Yongshuo Ji; Yu Zhang; Junqiu Zhu; Linglin Zhu; Yanfei Zhu; Kaimeng Hu; Hong Zhao
Journal:  Cancer Manag Res       Date:  2018-10-09       Impact factor: 3.989

8.  Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells.

Authors:  Justyna Kutkowska; Leon Strzadala; Andrzej Rapak
Journal:  Int J Mol Sci       Date:  2018-10-19       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.